Two new groundbreaking drugs could slow the memory impairment, thinking skills and overall brain decline — and both are ...

A breakthrough new Alzheimer’s disease treatment is stopping neurodegeneration in its tracks, even before symptoms appear.

A new study identifies certain neurotoxins responsible for brain inflammation common to early on-set Alzheimer's disease and an oral medication that treats it.

Growing evidence suggests that the key to treating Alzheimer's is catching it in its earliest stages. Now scientists have ...

After seeking care for escalating memory lapses, Diane Roussel received a devastating Alzheimer's diagnosis. She began ...

US FDA accepts Axsome Therapeutics’ supplemental New Drug Application for AXS-05 to treat Alzheimer’s disease agitation: New York Saturday, January 3, 2026, 12:00 Hrs [IST] Ax ...

New research suggests Alzheimer’s may start far earlier than previously thought, driven by a hidden toxic protein in the brain. Scientists found that an experimental drug, NU-9, blocks this early ...

FDA grants priority review to Axsome's AXS-05 for treating agitation in Alzheimer's disease with a PDUFA date of April 30, 2026.

The experimental drug lecanemab shows "potential" as an Alzheimer's disease treatment, according to new Phase 3 trial results, but the findings raise some safety concerns because of its association ...

The biopharmaceutical company accepted for filing a supplemental new drug application for AXS-05 to treat Alzheimer's disease agitation, and has granted the application priority review designation, ...

Shanghai Fosun Pharmaceutical Group Co. will acquire a controlling stake in a Chinese company that developed the country’s ...

FDA grants AXS-05 Priority Review designation and sets PDUFA action goal date of April 30, 2026NEW YORK, (GLOBE NEWSWIRE) -- ...